VivoSeq
Other

Facial Pain

19

Pipeline Programs↗

5

Active Trials↗

10

Companies Involved↗

Facial Pain is an emerging landscape with 19 programs across 10 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Pacira Pharmaceuticals, Inc, Revance Therapeutics, Inc.. 7 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

11/100

Mech. Concentration

15/100

Completion Rate

73/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2Pacira Pharmaceuticals, Inc logo

Pacira Pharmaceuticals, Inc

1 program

Phase 2R

Revance Therapeutics, Inc.

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2A

Allodynic Therapeutics, Inc

1 program

Phase 3Amgen logo

Amgen

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

22 of 23 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody14%

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed8 · 47%
Recruiting2 · 12%
Terminated2 · 12%
Enrolling by invitation2 · 12%
Not yet recruiting1 · 6%
Unknown status1 · 6%
Other1 · 6%

Clinical Trials

Trial Activity

17 trials

Botulinumtoxin A as a Treatment for Myalgia and Myofacial Pain in Patient With Temporomandibulardisorders
Recruiting·—·Phase 3·NCT06941636·90 enrolled
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
Recruiting·SStanford University·Phase 2·NCT04930887·15 enrolled
Safety and Efficacy of Lidocaine Versus Ketamine Infusion for Resistant Orofacial Pain
Not yet recruiting·—·Phase 2·NCT07250867·105 enrolled
Treatment of Atypical Resistant Facial Pain
Enrolling by invitation·—·N/A·NCT07250984·10 enrolled
The Effectiveness of CBD and CBN in the Treatment of Facial Pain and Headache of Muscular Origin
Enrolling by invitation·WWroclaw Medical University·Phase 2/3·NCT05961501·42 enrolled
Botox Injections for Patients With Persistent Facial Pain
Completed·NNorwegian University of Science and Technology·Phase 2·NCT03462290·31 enrolled
Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI
Completed·PPain and Analgesia Imaging and Neuroscience Group·N/A·NCT00243152·6 enrolled
Studies of Dextromethorphan and Topiramate to Treat Oral and Facial Pain
Completed·National Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT00001725·100 enrolled
Erenumab for Idiosyncratic Facial Pain
Completed·—·Phase 4·NCT04249427·29 enrolled
Transnasal Versus Suprazygomatic SPG Block in Persistant Idiopathic Facial Pain
Completed·—·N/A·NCT06496841·40 enrolled
Study of Orofacial Pain and PropRANOlol
Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT02437383·200 enrolled
Acute Effects of Alcohol Use on Chronic Orofacial Pain
Completed·UUniversity of Florida·N/A·NCT04019093·48 enrolled
Ultrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain
Completed·NNorthwestern University·Phase 4·NCT02024724·60 enrolled
Sinusitis and Facial Pain Disorders Anti-Depression Trial
Terminated·UUniversity of Washington·Phase 4·NCT00754793·3 enrolled
Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain
Terminated·UUniversity of California, San Francisco·N/A·NCT00716807·46 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)